Clearstone Central Laboratories
, a provider of central laboratory services for clinical trials, announced that it intends to sell or wind down over time its Centralized Cardiac Services (CCS) business in order to focus on its core laboratory business.
“Clearstone has set out to be a market leader, and in doing so we have had to make some strategic decisions to position the business for service excellence and growth. This action allows us to focus all of our efforts on further developing our core laboratory business” said Clearstone CEO Lewis Cameron. “We will continue to make significant investments in our facilities, people, technology and processes to better serve our clients. Recent examples include the expansion of testing capabilities at our Beijing and Toronto sites in response to market needs, and continued investment in our central laboratory protocol management system APOLLO CLPM™.”
The company also announced a restructuring due in part to this strategic repositioning. As such, a number of positions will be affected at the company’s Baillet lab operations in Paris, France. “It will take some months to work through the redundancy plan with our Baillet Works Council in accordance with French labour laws” added Mr. Cameron. “We will be taking every step possible to support affected staff and continue providing clients with the highest level of service during the transition period. In the meantime it is very much business as usual in our core laboratory operations, and we look to the future with great optimism as we continue to focus on service delivery and growth in emerging markets.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.